N11102014

    About  Us       R & D        Pipeline          Partnership           Investor Center         News & Events          Careers

Investor Center Partership News & Events Pipeline Research & Development About Us
Press Releases
More Ascletis News
Copyright © 2011 Ascletis Inc. All rights reserved.
Careers News & Events
 Home            Contact  

ascletis

   Home

Nov 10, 2014   Ascletis gains exclusive China market rights from Presidio to  clinical stage hepatitis C virus (HCV) NS5A inhibitor PPI-668  >>

N11102014 浙ICP备11050387号

中文

   Home-Ch Contact    Home

Mar 18, 2015   Ascletis’s HCV drug ASC08 Phase 2 data presented at annual Asian-Pacific Association for the Study of Liver  >>

N03182015

Mar 19, 2015   Special report of Ascletis’  ASC08 by  Zhejiang Daily  on China’s Protect Liver Day  >>

Mar 23, 2015   BioWorld Today - Ascletis’ triple theray HCV drug nails phase II trial in Chinese patients  >>

Oct 28, 2014   Ascletis to build commercial cGMP facility in Shaoxing Binhai New City  >>

N10282014 ZhejiangDaily20150319.pdf BioWorld20150323.pdf

Think Outside the Box

Research & Development
Partnership
Pipeline
Research & Development Partership

Ascletis is a specialty therapeutics company dedicated to discovering

and developing important new treatments for cancer and infectious diseases.

Pipeline
HIV in China

Status and Treatment Trends of HCV

HCV IN CHINA

HCV

Danoprevir